A SEER population analysis of stage IB resected gastric cancer: who can benefit from adjuvant therapy?

References

• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Miyahara R, Niwa Y, Matsuura T, et al. Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years. J Gastroenterol Hepatol. 2007;22(9):1435–1442.
   PubMed Web of Science ®Google Scholar
• Desai AM, Pareek M, Nightingale PG, et al. Improving outcomes in gastric cancer over 20 years. Gastric Cancer. 2004;7(4):196–201.
   PubMedGoogle Scholar
• Songun I, Putter H, Kranenbarg E-K, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–449.
   PubMed Web of Science ®Google Scholar
• Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol. 2004;22(14):2767–2773.
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–730.
   PubMed Web of Science ®Google Scholar
• Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-Directed Intergroup Study 0116: a Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection. J Clin Oncol. 2012;30(19):2327–2333.
   PubMed Web of Science ®Google Scholar
• Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–1820.
   PubMed Web of Science ®Google Scholar
• Noh SH, Park SR, Yang H-K, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389–1396.
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99.
   PubMed Web of Science ®Google Scholar
• Waddell T, Verheij M, Allum W, et al. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 (Suppl. 6):vi57–vi63.
   PubMed Web of Science ®Google Scholar
• Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19.
   Web of Science ®Google Scholar
• Park JH, Ryu MH, Kim HJ, et al. Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. Gastric Cancer. 2016;19(1):226–233.
   PubMed Web of Science ®Google Scholar
• Du C, Zhou Y, Huang K, et al. Defining a high-risk subgroup of pathological T2N0 gastric cancer by prognostic risk stratification for adjuvant therapy. J Gastrointest Surg. 2011;15(12):2153–2158.
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Kamada K, Tsurui Y, et al. Clinicopathological analysis for recurrence of stage Ib gastric cancer (according to the second English edition of the Japanese classification of gastric carcinoma). Gastric Cancer. 2011;14(4):372–377.
   PubMed Web of Science ®Google Scholar
• Gold JS, Al Natour RH, Saund MS, et al. Population-based outcome of stage IA-IIA resected gastric adenocarcinoma: who should get adjuvant treatment? Ann Surg Oncol. 2013;20(7):2304–2310.
   PubMed Web of Science ®Google Scholar
• Lee KG, Lee HJ, Oh SY, et al. Is there any role of adjuvant chemotherapy for T3N0M0 or T1N2M0 gastric cancer patients in stage II in the 7th TNM but stage I in the 6th TNM system? Ann Surg Oncol. 2016;23(4):1234–1243.
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565–574.
   PubMed Web of Science ®Google Scholar
• Kerr KF, Brown MD, Zhu K, et al. Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol. 2016;34(21):2534–2540.
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Cronin AM, Elkin EB, et al. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8(1):53.
   PubMed Web of Science ®Google Scholar
• Talluri R, Shete S. Using the weighted area under the net benefit curve for decision curve analysis. BMC Med Inform Decis Mak. 2016;16(1):94.
   PubMed Web of Science ®Google Scholar
• Zhao B, Huang X, Zhang J, et al. Clinicopathologic factors associated with recurrence and long-term survival in node-negative advanced gastric cancer patients. Rev Esp Enferm Dig. 2018;111:111–120.
   Web of Science ®Google Scholar
• Wang Y, Zhang J, Guo S, et al. Implication of lymph node staging in migration and different treatment strategies for stage T2N0M0 and T1N1M0 resected gastric cancer: a SEER population analysis. Clin Transl Oncol. 2019;21(11):1499–1509.
   PubMed Web of Science ®Google Scholar
• Kim Y, Spolverato G, Ejaz A, et al. A nomogram to predict overall survival and disease-free survival after curative resection of gastric adenocarcinoma. Ann Surg Oncol. 2015;22(6):1828–1835.
   PubMed Web of Science ®Google Scholar
• Huang ZN, Chen QY, Zheng CH, et al. Are the indications for postoperative radiotherapy in the NCCN guidelines for patients with gastric adenocarcinoma too broad? A study based on the SEER database. BMC Cancer. 2018;18(1):1064.
   PubMed Web of Science ®Google Scholar
• Lu J, Chen Y, Liu Y, et al. Clinical significance of prognostic score based on age, tumor size, and grade in gastric cancer after gastrectomy. Cancer Manag Res. 2018;10:4279–4286.
   PubMed Web of Science ®Google Scholar
• Ye S, Bai L. Comparison and validation of the value of preoperative inflammation marker-based prognostic scores in resectable pancreatic ductal adenocarcinoma. Cancer Manag Res. 2018;10:3405–3417.
   PubMed Web of Science ®Google Scholar
• Roberto M, Botticelli A, Strigari L, et al. Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival. Med Oncol. 2018;35(7):111.
   PubMed Web of Science ®Google Scholar
• Zheng ZF, Lu J, Wang W, Desiderio J, et al. Development and external validation of a simplified nomogram predicting individual survival after R0 resection for gastric cancer: an International, Multicenter Study. Ann Surg Oncol. 2018;25(8):2383–2390.
   PubMed Web of Science ®Google Scholar
• Ma M, Wang J, Hu Y, et al. Prognostic value of inflammatory biomarkers in gastric cancer patients and the construction of a predictive model. Dig Surg. 2018;36:1–10.
   PubMed Web of Science ®Google Scholar
• Pan Y, Hong Y, Liang Z, et al. Survival analysis of distant metastasis of laryngeal carcinoma: analysis based on SEER database. Eur Arch Otorhinolaryngol. 2019;276(1):193–201.
   PubMed Web of Science ®Google Scholar
• Lai JF, Kim S, Kim K, et al. Prediction of recurrence of early gastric cancer after curative resection. Ann Surg Oncol. 2009;16(7):1896–1902.
   PubMed Web of Science ®Google Scholar
• Kunisaki C, Makino H, Kimura J, et al. Impact of lymphovascular invasion in patients with stage I gastric cancer. Surgery. 2010;147(2):204–211.
   PubMed Web of Science ®Google Scholar
• Fitzgerald M, Saville BR, Lewis RJ. Decision curve analysis. JAMA. 2015;313(4):409–410.
   PubMed Web of Science ®Google Scholar
• Hernandez JM, Tsalatsanis A, Humphries LA, et al. Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis. Ann Surg. 2014;259(6):1208–1214.
   PubMed Web of Science ®Google Scholar
• Wynants L, Timmerman D, Verbakel JY, et al. Clinical utility of risk models to refer patients with adnexal masses to specialized oncology care: multicenter external validation using decision curve analysis. Clin Cancer Res. 2017;23(17):5082–5090.
   PubMed Web of Science ®Google Scholar
• Zastrow S, Brookman-May S, Cong TA, et al. Decision curve analysis and external validation of the postoperative Karakiewicz nomogram for renal cell carcinoma based on a large single-center study cohort. World J Urol. 2015;33(3):381–388.
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075.
   PubMed Web of Science ®Google Scholar